June 29, 2016 - Gilead, a ubiquitous genotypic hepatitis C cocktail therapy in the field of hepatitis C, has made a major milestone in the US regulation, Epclusa. FDA has approved Epclusa for the treatment of all 6 genotypes of hepatitis C.

July 9, 2016 - the ubiquitous gene type hepatitis C cocktail therapy (Epclusa) developed by Gilead, the absolute hegemon in the field of hepatitis C, has achieved a major milestone in the United States

Lung cancer is one of the most malignant tumors with the fastest growth rate of morbidity and mortality and the most serious threat to peoples health and life. In the past 50 years, many countries have reported that the incidence and mortal